Study guide
6.7 Gastrointestinal and Hepatic Pharmacotherapy
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
6.7 Gastrointestinal and Hepatic Pharmacotherapy
Key Takeaways Explain This Topic AI
Alarm features in dyspepsia — dysphagia, unintended weight loss, gastrointestinal bleeding, persistent vomiting, anemia, or new onset after age 50 — require medical referral rather than a non-prescription trial.
Helicobacter pylori is treated in Canada with a 14-day quadruple regimen; clarithromycin-based triple therapy is no longer reliable because of resistance rates above 15%.
Long-term proton pump inhibitor therapy without a documented ongoing indication is a leading deprescribing target, and abrupt discontinuation causes rebound acid hypersecretion that mimics relapse.
Spontaneous bacterial peritonitis is diagnosed on ascitic fluid with 250 or more polymorphonuclear cells per cubic millimetre and is treated with a third-generation cephalosporin plus albumin.
Lactulose is titrated in hepatic encephalopathy to produce two or three soft stools per day, with rifaximin added for recurrent episodes.
Last updated: August 2026
6.7 Gastrointestinal and Hepatic Pharmacotherapy
Exam Focus: Gastrointestinal complaints reach pharmacists more often than almost any other therapeutic area, so the Evaluating Examination pairs them with triage judgement: recognise the alarm feature, choose the guideline-consistent regimen, and know when the safest recommendation is to stop a drug.
- Acid-Related Disorders
- Gastroesophageal reflux disease
GERD is retrograde movement of gastric contents causing troublesome symptoms or mucosal injury. Typical presentations are heartburn and regurgitation; atypical ones include chronic cough, hoarseness, and non-cardiac chest pain.
Stepwise therapy:
Non-pharmacological: weight loss where relevant, elevate the head of the bed, avoid eating within three hours of lying down, and identify individual triggers rather than imposing a blanket exclusion diet.
Antacids or alginate for infrequent, predictable symptoms.
Histamine-2 receptor antagonist (famotidine) for mild intermittent symptoms; tachyphylaxis develops within about two weeks of scheduled use.
Proton pump inhibitor (PPI) once daily 30 to 60 minutes before the first meal for frequent or erosive disease.
Alarm features requiring referral
Do not sell a non-prescription acid suppressant to a patient with dysphagia, odynophagia, unintended weight loss, hematemesis, melena, persistent vomiting, iron-deficiency anemia, a palpable mass, or new-onset dyspepsia after age 50 . Each raises the probability of malignancy, stricture, or ulcer bleeding.
Peptic ulcer disease and Helicobacter pylori
The two dominant causes are H. pylori infection and non-steroidal anti-inflammatory drug (NSAID) use. Because Canadian clarithromycin resistance now exceeds the 15% threshold at which triple therapy fails, first-line eradication is a 14-day quadruple regimen :
- Regimen Components Duration
- Bismuth quadruple PPI + bismuth subsalicylate + metronidazole + tetracycline 14 days
- Concomitant non-bismuth quadruple PPI + amoxicillin + metronidazole + clarithromycin 14 days
Counsel that bismuth blackens the tongue and stool (harmless, and distinguishable from melena by the absence of other bleeding signs) and that metronidazole with alcohol can produce a disulfiram-like reaction. Confirm eradication with a urea breath test or stool antigen test at least four weeks after antibiotics and at least two weeks after stopping the PPI, because earlier testing gives false negatives.
Deprescribing proton pump inhibitors
PPIs continued without a documented indication are associated with Clostridioides difficile infection, community-acquired pneumonia, hypomagnesemia, vitamin B12 malabsorption, and fracture. Indications justifying continuation include Barrett esophagus, severe erosive esophagitis, chronic NSAID use with risk factors, and Zollinger-Ellison syndrome. Otherwise, taper the dose or move to on-demand use, and warn the patient about rebound acid hypersecretion in the first two weeks so that transient heartburn is not misread as disease relapse.
Inflammatory Bowel Disease
- Feature Crohn disease Ulcerative colitis
- Distribution Mouth to anus, skip lesions Continuous, rectum proximally
- Depth Transmural Mucosal and submucosal
- Classic complications Fistulae, strictures, abscess Toxic megacolon, colorectal cancer
- Smoking Worsens disease Paradoxically associated with lower risk
- 5-Aminosalicylate role Limited Cornerstone of mild to moderate disease
Therapy escalates from 5-aminosalicylates (ulcerative colitis) through corticosteroids for induction only, to immunomodulators (azathioprine, methotrexate) and biologics (infliximab, adalimumab, vedolizumab, ustekinumab). Before any anti-tumour necrosis factor agent, screen for latent tuberculosis and hepatitis B. Patients on azathioprine need thiopurine methyltransferase (TPMT) or NUDT15 assessment, since deficiency causes profound myelosuppression at standard doses.
Irritable Bowel Syndrome, Constipation, and Diarrhea
Irritable bowel syndrome is a disorder of gut-brain interaction diagnosed by recurrent abdominal pain related to defecation or a change in stool form or frequency, without alarm features. Management is subtype-directed: soluble fibre such as psyllium and, where appropriate, a low fermentable oligosaccharide, disaccharide, monosaccharide and polyol (FODMAP) diet; antispasmodics for pain; polyethylene glycol for constipation-predominant disease; loperamide for diarrhea-predominant disease. Low-dose tricyclic antidepressants act as neuromodulators, not as antidepressant therapy.
Constipation management begins with fibre and fluid, then an osmotic agent (polyethylene glycol is preferred), with stimulants such as sennosides or bisacodyl for short-term rescue. Opioid-induced constipation does not adapt over time; start a stimulant laxative prophylactically at the same time as the opioid, and reserve peripherally acting mu-opioid receptor antagonists for refractory cases. Docusate has repeatedly failed to outperform placebo and should not be the recommendation.
Acute diarrhea is usually self-limiting; oral rehydration is the priority. Loperamide is inappropriate when there is bloody diarrhea or high fever, because slowing transit in invasive or toxin-mediated infection increases the risk of toxic megacolon and haemolytic uremic syndrome.
Nausea and Vomiting
Match the antiemetic to the mechanism:
Motion sickness (vestibular): dimenhydrinate, scopolamine.
Pregnancy: doxylamine-pyridoxine is the first-line and best-studied option in Canada.
Chemotherapy-induced: 5-hydroxytryptamine-3 antagonists (ondansetron), neurokinin-1 antagonists (aprepitant), dexamethasone, and olanzapine in highly emetogenic regimens.
Gastroparesis or delayed emptying: metoclopramide, limited to short courses because of tardive dyskinesia risk.
Ondansetron prolongs the QT interval; check for concurrent QT-prolonging drugs and electrolyte disturbance.
Cirrhosis and Its Complications
Portal hypertension drives most of the complications a pharmacist manages.
Complication First-line management Monitoring
Ascites Sodium restriction, spironolactone with furosemide in a 100:40 mg ratio Weight, sodium, potassium, renal function
Spontaneous bacterial peritonitis Third-generation cephalosporin plus intravenous albumin; ascitic polymorphonuclear count of 250/mm3 or more confirms Fever, abdominal pain, encephalopathy
Hepatic encephalopathy Lactulose titrated to 2 to 3 soft stools daily; add rifaximin for recurrence Mental status, asterixis
Variceal bleeding prophylaxis Non-selective beta-blocker (nadolol, propranolol, carvedilol) or band ligation Heart rate, blood pressure
Acetaminophen remains the preferred analgesic in stable cirrhosis at a reduced ceiling of about 2 g per day. NSAIDs are avoided because they precipitate renal failure and bleeding; benzodiazepines are avoided because they precipitate encephalopathy.